Clinical trial
Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With…
NCT00498836 · Clavis Pharma, Industry · Completed
Key facts
| NCT number | NCT00498836 |
|---|---|
| Title | Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma |
| Official title | A Multicentre, Dose Finding, Phase II Study of CP-4055 in Combination With Sorafenib in Patients With Metastatic Malignant Melanoma |
| Lead sponsor | Clavis Pharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Drug |
| Interventions | CP-4055, Sorafenib (Nexavar) |
| Enrollment | 18 |
| Start date | Mar 1, 2007 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Jul 10, 2007 |
| Last update posted | Sep 12, 2013 |
| Countries | Norway, Sweden, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: